OBJECTIVE: To report on the natural history of high-risk human papillomavirus (HPV) infection and cervical disease in human immunodeficiency virus (HIV)-1-infected women living in Cape Town, South Africa. METHODS: This was a prospective study of 400 untreated, HIV-1-infected women who underwent high-risk HPV DNA testing, cytology, colposcopy, histology, and CD4 count testing every 6 months for 36 months. Human immunodeficiency virus viral loads and HPV type distribution were determined at entry and after 18 months. RESULTS: Sixty-eight percent of the women were high-risk HPV DNA positive at entry, 35% had a cytologic diagnosis of low-grade squamous intraepithelial lesion (LSIL), and 13% had high-grade squamous intraepithelial lesion (HSIL). There were no cancers. Abnormal cytology and high-risk HPV positivity were strongly correlated with low CD4 counts and high HIV viral loads. The most prevalent types of HPV were HPV-16, -52, -53, -35, and -18. Incident high-risk HPV infection occurred in 22%, and of those infected with high-risk HPV, 94% of infections persisted over an 18-month period, and 6% cleared their infections. Cytologic progression to SIL from normal/atypical squamous cells of undetermined significance cytology occurred in 17% of cases, but only 4% of cases of LSIL progressed to HSIL. CONCLUSION: There is a high level of high-risk HPV infection in HIV-1 infected women, but progression to HSIL over 36 months occurred in the minority of cases. We recommend an initial colposcopy for an abnormal test, and if no high-grade lesion is identified, triennial screening would be appropriate. Human papillomavirus type 16 was the commonest, and HPV-18 was the fifth commonest, suggesting that vaccination against these two types would have a significant effect. LEVEL OF EVIDENCE: II.
OBJECTIVE: To report on the natural history of high-risk human papillomavirus (HPV) infection and cervical disease in human immunodeficiency virus (HIV)-1-infected women living in Cape Town, South Africa. METHODS: This was a prospective study of 400 untreated, HIV-1-infectedwomen who underwent high-risk HPV DNA testing, cytology, colposcopy, histology, and CD4 count testing every 6 months for 36 months. Human immunodeficiency virus viral loads and HPV type distribution were determined at entry and after 18 months. RESULTS: Sixty-eight percent of the women were high-risk HPV DNA positive at entry, 35% had a cytologic diagnosis of low-grade squamous intraepithelial lesion (LSIL), and 13% had high-grade squamous intraepithelial lesion (HSIL). There were no cancers. Abnormal cytology and high-risk HPV positivity were strongly correlated with low CD4 counts and high HIV viral loads. The most prevalent types of HPV were HPV-16, -52, -53, -35, and -18. Incident high-risk HPV infection occurred in 22%, and of those infected with high-risk HPV, 94% of infections persisted over an 18-month period, and 6% cleared their infections. Cytologic progression to SIL from normal/atypical squamous cells of undetermined significance cytology occurred in 17% of cases, but only 4% of cases of LSIL progressed to HSIL. CONCLUSION: There is a high level of high-risk HPV infection in HIV-1 infectedwomen, but progression to HSIL over 36 months occurred in the minority of cases. We recommend an initial colposcopy for an abnormal test, and if no high-grade lesion is identified, triennial screening would be appropriate. Human papillomavirus type 16 was the commonest, and HPV-18 was the fifth commonest, suggesting that vaccination against these two types would have a significant effect. LEVEL OF EVIDENCE: II.
Authors: Tanvier Omar; Sheree Schwartz; Colleen Hanrahan; Tebogo Modisenyane; Nkeko Tshabangu; Jonathan E Golub; James A McIntyre; Glenda E Gray; Lerato Mohapi; Neil A Martinson Journal: AIDS Date: 2011-01-02 Impact factor: 4.177
Authors: Scott Dryden-Peterson; Memory Bvochora-Nsingo; Gita Suneja; Jason A Efstathiou; Surbhi Grover; Sebathu Chiyapo; Doreen Ramogola-Masire; Malebogo Kebabonye-Pusoentsi; Rebecca Clayman; Abigail C Mapes; Neo Tapela; Aida Asmelash; Heluf Medhin; Akila N Viswanathan; Anthony H Russell; Lilie L Lin; Mukendi K A Kayembe; Mompati Mmalane; Thomas C Randall; Bruce Chabner; Shahin Lockman Journal: J Clin Oncol Date: 2016-11-01 Impact factor: 44.544
Authors: R A Hanisch; P S Sow; M Toure; A Dem; B Dembele; P Toure; R L Winer; J P Hughes; G S Gottlieb; Q Feng; N B Kiviat; S E Hawes Journal: J Clin Virol Date: 2013-10-18 Impact factor: 3.168
Authors: Jennifer R Moodley; Deborah Constant; Margaret Hoffman; Anna Salimo; Bruce Allan; Ed Rybicki; Inga Hitzeroth; Anna-Lise Williamson Journal: BMC Cancer Date: 2009-08-07 Impact factor: 4.430
Authors: Vikrant V Sahasrabuddhe; Ramesh A Bhosale; Smita N Joshi; Anita N Kavatkar; Chandraprabha A Nagwanshi; Rohini S Kelkar; Cathy A Jenkins; Bryan E Shepherd; Seema Sahay; Arun R Risbud; Sten H Vermund; Sanjay M Mehendale Journal: PLoS One Date: 2010-01-08 Impact factor: 3.240
Authors: Cynthia Firnhaber; Hoa Van Le; Audrey Pettifor; Doreen Schulze; Pam Michelow; Ian M Sanne; David A Lewis; Anna-Lise Williamson; Bruce Allan; Sophia Williams; Allen Rinas; Simon Levin; Jennifer S Smith Journal: Cancer Causes Control Date: 2009-12-01 Impact factor: 2.506